Copertina

Lipolysis‐Stimulated Lipoprotein Receptor Gene Variants as a Cause of Progressive Familial Intrahepatic Cholestasis: A Case Report

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Yugo Takaki, Shuichiro Umetsu, Yoshihiko Sugino, Takahiro Yamashita, Takehiko Doi, Kazuo Imagawa, Shogo Ito, Yutaro Mihara, Hisamitsu Hayashi, Ayano Inui
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Hepatology Research
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Cholestasis Linked to Bodybuilding Supplements: Exploring the Risks of Contamination
di: Mark Matusak, et al.
Pubblicazione: (2024)

Mac‐2 Binding Protein Glycosylation Isomer as a Dynamic Biomarker in Obstructive Cholestasis
di: Takanobu Iwadare, et al.
Pubblicazione: (2025)

Digital Polymerase Chain Reaction‐Based Fecal Streptococcus Quantification for Liver Fibrosis Assessment in Chronic Liver Disease
di: Nomura Nao, et al.
Pubblicazione: (2025)

Gastrointestinal: Colorectal metastases from gastric poorly differentiated carcinoma presenting as a diminutive polyp
di: K Shiotsuki, et al.
Pubblicazione: (2024)

Regeneration of the Human Intrahepatic Nervous System in Living Donor Liver Transplantation Recipients
di: Yusuke Hanabata, et al.
Pubblicazione: (2026)

Clinical Impact of Recurrence Beyond the Milan Criteria After Curative Resection of Hepatocellular Carcinoma
di: Takeshi Terashima, et al.
Pubblicazione: (2025)

SOX9 Is a Key Factor for the Postnatal Maturation of the Intrahepatic Bile Duct Network
di: Hiroki Hirao, et al.
Pubblicazione: (2025)

Deep‐Learning‐Aided Quantification of Steatohepatitis‐Associated Pathological Findings in Liver Specimens
di: Shinji Mizuochi, et al.
Pubblicazione: (2025)

Efficacy and Safety of Glecaprevir/Pibrentasvir in Children Aged 3–11 Years With Chronic Hepatitis C: A Real‐World, Prospective, Multicenter Study in Japan
di: Tatsuki Mizuochi, et al.
Pubblicazione: (2025)

Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab
di: Kazunari Tanaka, et al.
Pubblicazione: (2026)

Clonorchis sinensis Promotes Intrahepatic Cholangiocarcinoma Progression by Activating FASN‐Mediated Fatty Acid Metabolism
di: Xiaoxue Ren, et al.
Pubblicazione: (2025)

FGFR2 Fusions or Rearrangements in Young Intrahepatic and Perihilar Cholangiocarcinoma Patients: Key Genetic Insights From a Pan‐Asian Study
di: Yuta Maruki, et al.
Pubblicazione: (2025)

Improvement in Irretractable Pruritus With Intrahepatic Portosystemic Shunt Embolization: From MAID to a New Lease on Life
di: Amitesh Bagha, et al.
Pubblicazione: (2026)

Steatotic Liver Disease and the “Point of No Return” in the Development of Metabolic Disorders
di: Tsutomu Nishida, et al.
Pubblicazione: (2026)

Is Glucose Intolerance a Precursor of Cachexia in Patients With Liver Cirrhosis?
di: Tsutomu Nishida, et al.
Pubblicazione: (2025)

Intrahepatic Cholangiocarcinoma: Epidemiological Trends, Risk Factors, Diagnostic Challenges, and Advances in Personalized Therapy—A Comprehensive Review
di: Yaqoob Muhammad, et al.
Pubblicazione: (2026)

Pathological changes of a malignant liver tumor after systemic therapies
di: Shinya Kuwabara, et al.
Pubblicazione: (2025)

Single‐Cell Transcriptomic Analysis Reveals an Aggressive Basal‐Like Tumor Cell Subpopulation Associated With Poor Prognosis in Intrahepatic Cholangiocarcinoma
di: Changyi Liao, et al.
Pubblicazione: (2025)

High Intrahepatic cccDNA in Resolved HBV Infection: Insights From Living Donor Liver Transplantation With Anti‐HBc‐Positive Grafts
di: Sung Kwan Bae, et al.
Pubblicazione: (2026)

Oncogenic LPCAT1 Accelerates Intrahepatic Cholangiocarcinoma Development Through PI3K/Akt Signaling‐Dependent Cell Cycle Regulation
di: Enlai Jiang, et al.
Pubblicazione: (2026)

Hepatic Mac2‐BP expression depends on liver fibrosis and inflammation due to fat accumulation in patients with metabolic dysfunction‐associated steatotic liver disease
di: Haruki Uojima, et al.
Pubblicazione: (2024)

Impact of the revised Japanese indication criteria for deceased donor liver transplantation on liver cirrhotic patients of Child–Pugh classification B with hepatocellular carcinoma
di: Akihiro Seki, et al.
Pubblicazione: (2025)

Impact of metabolic dysfunction‐associated fatty liver disease on the incidence of Helicobacter pylori‐negative gastric cancer
di: Tomoyuki Nakane, et al.
Pubblicazione: (2024)

Efficacy of steroid therapy for improving native liver survival after pediatric acute liver failure with immune activation
di: Hiroshi Oue, et al.
Pubblicazione: (2024)

Clinical benefits of partial splenic embolization for cancer patients
di: Toru Beppu, et al.
Pubblicazione: (2024)

Metabolic dysfunction‐associated steatotic liver disease (SLD) and alcohol‐associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10‐year follow‐up period
di: Kazuma Mori, et al.
Pubblicazione: (2024)

Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
di: Keishi Ouchi, et al.
Pubblicazione: (2026)

Persistent acute kidney injury: Postoperative impact and predictors in patients undergoing liver resection
di: Shunsuke Doi, et al.
Pubblicazione: (2024)

Total bile acids levels as a stratification tool for screening portopulmonary hypertension in patients with decompensated cirrhosis
di: Kazuaki Tajima, et al.
Pubblicazione: (2024)

Large, White Globe Appearance–Like Endoscopic Findings: Stomach Lymphatic Invasion Distant From Advanced Gastric Cancer
di: Kohei Uyama, et al.
Pubblicazione: (2026)

Biopsy‐Proven Reversal of F4 Cirrhosis in Classic Hepatic Glycogen Storage Disease Type IV: A 42‐Year Follow‐Up Without Transplantation
di: Masaaki Mino, et al.
Pubblicazione: (2025)

Characteristics of diabetes mellitus patients with nonviral chronic liver disease who developed hepatocellular carcinoma
di: Kyo Sasaki, et al.
Pubblicazione: (2024)

Grip strength is a strong indicator of osteoporosis in both women and men with chronic liver disease
di: Tatsuki Ichikawa, et al.
Pubblicazione: (2025)

Plasma Vascular Endothelial Growth Factor‐A Identified by Proximity Extension Assay Predicts Early Progression in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab
di: Kazuaki Tajima, et al.
Pubblicazione: (2025)

Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study
di: Tomoki Hori, et al.
Pubblicazione: (2026)

Brief intervention for chronic liver disease patients with alcohol use disorder in a hepatology outpatient unit: Effects and limitations
di: Nagisa Hara, et al.
Pubblicazione: (2024)

Randomized Controlled Trial of Endoscopic Ultrasound‐Guided Liver Biopsy Versus Percutaneous Liver Biopsy for Obtaining Histologically Adequate Specimens
di: Kosuke Okuwaki, et al.
Pubblicazione: (2026)

Unmasking Aspiration Risks: A Propensity‐Matched Odyssey of GLP‐1 Receptor Agonists and Colonoscopy
di: Puneet Chhabra, et al.
Pubblicazione: (2025)

Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination
di: Yuta Myojin, et al.
Pubblicazione: (2025)

The Effects of CD100 Stimulation on Primary Human Hepatocytes (PHHs) and Its Implications in HBV‐Related Liver Cirrhosis
di: Chao Fan, et al.
Pubblicazione: (2025)